- Book Chapter
- 10.1007/978-3-662-67528-1_11
Trachealkanülen-Management in der F.O.T.T.: der Weg zurück zur Physiologie
- Jan 01, 2023
- Heike Sticher + 1 more +1
Publications from 2021 to 2026
Showing 8 of 8 papers
Trachealkanülen-Management in der F.O.T.T.: der Weg zurück zur Physiologie
Optimizing home-based long-term intensive care for neurological patients with neurorehabilitation outreach teams – protocol of a multicenter, parallel-group randomized controlled trial (OptiNIV-Study)
BackgroundEven with high standards of acute care and neurological early rehabilitation (NER) a substantial number of patients with neurological conditions still need mechanical ventilation and/or airway protection by tracheal cannulas when discharged and hence home-based specialised intensive care nursing (HSICN). It may be possible to improve the home care situation with structured specialized long-term neurorehabilitation support and following up patients with neurorehabilitation teams. Consequently, more people might recover over an extended period to a degree that they were no longer dependent on HSICN.MethodsThis healthcare project and clinical trial implements a new specialised neurorehabilitation outreach service for people being discharged from NER with the need for HSICN. The multicentre, open, parallel-group RCT compares the effects of one year post-discharge specialized outpatient follow-up to usual care in people receiving HSICN. Participants will randomly be assigned to receive the new form of healthcare (intervention) or the standard healthcare (control) on a 2:1 basis. Primary outcome is the rate of weaning from mechanical ventilation and/or decannulation (primary outcome) after one year, secondary outcomes include both clinical and economic measures. 173 participants are required to corroborate a difference of 30 vs. 10% weaning success rate statistically with 80% power at a 5% significance level allowing for 15% attrition.DiscussionThe OptiNIV-Study will implement a new specialised neurorehabilitation outreach service and will determine its weaning success rates, other clinical outcomes, and cost-effectiveness compared to usual care for people in need for mechanical ventilation and/or tracheal cannula and hence HSICN after discharge from NER.Trial registrationThe trial OptiNIV has been registered in the German Clinical Trials Register (DRKS) since 18.01.2022 with the ID DRKS00027326.
Read moreThe F.O.T.T. Approach to Tracheostomy Tube Management (TTM): Return to Physiology
Die Welt des Tai Chi
Die Welt des Tai Chi
Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry
This study aimed at providing real-life baseline, injection and outcome data for the treatment of various forms of spasticity with onabotulinumtoxin A in Germany. Prospective data were collected in an open multicenter patient registry from 2005 until 2010, encompassing the experience of ten specialized German centers in the treatment of spasticity using onabotulinumtoxin A in 508 patients with a total of 2005 treatment sessions. Disease entities comprised spasticity following stroke (both ischemic and hemorrhagic), traumatic brain injury, multiple sclerosis, cerebral palsy, and anoxia. Sustained improvement was observed in a variety of outcome parameters including goal attainment and motor performance scores for up to five repeated injection sessions. No significant differences between disease entities or between upper and lower limb treatment were observed with regard to efficacy and safety following onabotulinumtoxin A treatment. Minor to moderate side effects were reported in <1% of the study population. We conclude that repetitive treatment of focal and multifocal spasticity with onabotulinumtoxin A provides a safe and efficacious therapeutic strategy for patients with different disease entities of the central nervous system.
Read moreBilateral loss of cortical SSEP responses is compatible with good outcome after cardiac arrest
Global cerebral ischemia (GCI) following cardiac arrest (CA) is often associated with a poor prognosis and longterm disorders of consciousness. Bilateral absence of cortical responses of the median nerve somatosensory evoked potentials (SSEP) is believed to predict poor outcome with almost 100 % specificity [1–4]. We report a case of a patient with good outcome despite repeatedly absent cortical SSEP responses and without hypothermia. A 16-year-old student suffered CA while playing soccer. Cardiopulmonary resuscitation began within 3 min. Initial rhythm analysis showed ventricular fibrillation (VF, Fig. 1a). Both pupils were dilated and unresponsive to light. After 25 min of resuscitation, stable cardiac output was reestablished and he was admitted to an intensive care unit. Despite the lack of sedative drugs, he was comatose. The GCS motor score was three and pupils were reactive to light. Because of aspiration pneumonia, the patient was ventilated and sedation was started with propofol, midazolam, and fentanyl for 48 h. Hypothermia was not induced, because this was only optional for children according to the 2005 European resuscitation council guidelines [5]. Neurological assessment after 72 h (with no sedation for the last 24) revealed a GCS of 5 (E1V1M3). At this time, median nerve SSEP were conducted in a specialized neurophysiology lab ([3000 recordings/year). N20 cortical responses were bilaterally absent (Fig. 1b). The EEG showed severe encephalopathy. Serum markers for neuronal damage were not examined. A brain CT scan after 96 h showed slight brain edema and obscuration of the caudate nucleus head (Fig. 1c). Based on the lack of arousal and the unfavourable SSEP results, the parents were informed about the diagnosis of severe GCI and the nearly inevitable poor prognosis. Because of a myoclonic status of the diaphragm, he was treated with repeated single doses of barbiturates and muscle relaxants on days 4–7. Sedation was discontinued on day 7, but again the patient failed to recover consciousness. On day 9, SSEP were repeated and again showed no signs of cortical N20 responses. He was extubated on day 12. On day 27, he was transferred to a specialized neurorehabilitation center in the minimally conscious state. He remained in inpatient rehabilitation for 7 months with constant improvement of neurological function. He was able to leave the rehabilitation facility on foot together with his mother (Fig. 1d). 3 years after cardiac arrest, the patient now lives at home with his parents (Barthel index 90/100 points). He rates his quality of life as 65 % (EuroQol, ranging from 0 to 100 %). Dysarthria and fine motor control problems are his biggest limitations on participation in life. A mutation in the SCN5A-gene was A. Bender (&) K. Howell M. Frey Department of Neurology, Therapiezentrum Burgau, Dr.-Friedl-Str. 1, 89331 Burgau, Germany e-mail: andreas.bender@med.uni-muenchen.de
Read moreBeyond herniation